<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_fosamprenavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:51 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Fosamprenavir</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">06-11-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>Currently not available in Zambia. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm.D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV-infected pts in combination with other ARVs</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top"><I>Lexiva (</I>U.S.); <I>Telzir</I> (Europe)</TD><TD valign="top">Fosamprenavir calcium (FPV)</TD><TD valign="top">GlaxoSmithKline</TD><TD>oral</TD><TD>tablet</TD><TD>700 mg</TD><TD>$12.75</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral </TD><TD>suspension </TD><TD>50 mg/ml (225 ml bottle) </TD><TD>&nbsp;$117.24&nbsp;</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 4 tabs/d (unboosted or boosted with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>)<br>
<br>
<ul>
<li>FPV 700 mg twice-daily  +&nbsp;<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg twice-daily with or w/o food (author's preference due to superior PK profile &amp; lack of resistance with failure) OR FPV 1400&nbsp;mg twice-daily with or w/o food OR FPV 1400 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100-200 mg once-daily  with or w/o food (once-daily dosing and unboosted regimen  for PI-naive pts only). </li>
<li>With <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: FPV 700 mg twice-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100 mg twice-daily + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs OR FPV 1400 mg once-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 300 mg once-daily + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs</li>
<li>With <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>: Generally not recommended. Consider FPV 1400 mg twice-daily + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 600/150 mg twice-daily with TDM</li>
<li>With <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>, <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>: Inadequate data; avoid co-administration.</li>
<li>With <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Not recommended</li>
<li>With <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>: Inadequate data; avoid or consider <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg once-daily + FPV/r 700/100 mg twice-daily . </li>
<li>With <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>: Inadequate data; avoid or consider <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>/r 1000/100-200 mg twice-daily + FPV 700 mg twice-daily. </li>
<li>With TPV: Not recommended. </li>
<li>With <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: FPV/r 700/100 mg twice-daily + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg twice-daily </li>
<li>With RAL: No data. Consider FPV/r 700/100 mg twice-daily + standard dose raltegravir with close monitoring. </li>
<li>With <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">ETR</A>: avoid co-administration per manufacturer, but clinical significance unclear. Consider FPV/r 700/100 mg twice-daily + standard dose <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">etravirine</A>. </li>
<li>With <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A>: no data. Consider FPV/r 700/100 mg twice-daily + MVC150 mg twice-daily. </li>
<li>With <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">DRV/r</A>: no data. Avoid co-administration. </li>
<li>FPV tablets and liquid formulations interchangeable, but liquid formulation should be administered on empty stomach in adults (but with food in children). </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>Usual dose <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>No data. Usual dose likely (on days of HD dose post HD). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>ADRs similar to comparator PIs (<A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> and <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>). GI intolerance and triglyceride elevation slightly higher compared to ATV/r. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>Rash in 12-33% of pts (&lt;1% require discontinuation).</li>
<li>GI intolerance in up to 40-53%% (severe in 5-10%). <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">Diarrhea</A> less common than with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>, but higher compared to ATV/r. . </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hyperlipidemia4edb.html?contentInstanceId=434827">Triglyceride and LDL elevation</A>(lower incidence compared to <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>); with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>&nbsp;(200 mg/d) co-administration, incidence of hypertriglyceridemia (&gt;750 mg/dL) was 11%. &nbsp;With FPV/r 1400/100 mg once-daily, LDL elevation comparable to ATV/r; however, triglyceride elevation was slightly higher in the FPV/r treated group (34 vs 7 g/dL increase from baseline). </li>
<li>
          
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/diabetes_mellitus_and_insulin_resistance382a.html?contentInstanceId=432783">Insulin resistance</A>
        
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hepatotoxicity0e98.html?contentInstanceId=434823">Elevated </A>transaminases in 6-8% </li>
<li>
          
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Fat accumulation</A>
        
</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Stevens-Johnson syndrome reported. FPV has a sulfa moiety; incidence of cross-reaction with other sulfa drugs unknown. Use with caution in pts with severe skin reaction secondary to sulfonamides. </li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Substrate, inhibitor, and likely an inducer of CYP3A4. CYP3A4 inhibitors may increase APV levels. CYP3A4 inducers may decrease APV levels. FPV may increase or decrease levels of CYP3A4 substrates. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A>&nbsp;</B></TD><TD valign="top">No data </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>
          </B></TD><TD valign="top">FPV 700 mg twice-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg twice-daily + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs x 2 wks: APV Cmin decreased by 17% compared to twice-daily boosted FPV. FPV 1400 mg once-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg once-daily + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs x 2 wks: APV Cmin decreased by 36% with <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> co-administration compared to once-daily boosted FPV.</TD><TD valign="top">Recommended dose: FPV 700 mg twice-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg twice-daily + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg once-daily OR FPV 1400 mg once-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 300 mg once-daily + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r </A>
          </B></TD><TD valign="top">FPV 1400mg twice-daily + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 533mg/133mg twice-daily: APV Cmin decreased by 42% (compared to FPV 700mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100mg twice-daily) but 3-fold higher Cmin (compared to FPV1400mg twice-daily historical control); no significant change in <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A> serum levels (compared to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 400mg/100mg twice-daily).</TD><TD valign="top">Co-administration generally not recommended. Consider FPV 1400 mg twice-daily + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 600/150 mg twice-daily. Consider TDM with co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">No data, but significant decrease in APV serum levels expected.</TD><TD valign="top">Co-administration not recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>
          </B></TD><TD valign="top">When co-administered with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, APV AUC increased by over 2-fold, Cmin increased by 4-fold w/ once-daily administration and 6-fold w/ twice-daily administration (compared to FPV 1400mg twice-daily).</TD><TD valign="top">Dose for PI experienced pts: FPV 700 mg twice-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg twice-daily. Daily administration (FPV 1400 mg once-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg once-daily) can be used in PI-naive pts.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A>
          </B></TD><TD valign="top">Interaction unlikely </TD><TD valign="top">Use standard doses of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A>
          </B></TD><TD valign="top">May increase <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">clarithromycin</A> AUC with FPV/r </TD><TD valign="top">No data with FPV, but APV increased 18% with <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">clarithromycin</A> co-administration. Consider dose adjustment renal insufficiency. CrCl 30-60 ml/min: 50% of dose. &lt;30ml/min: 25% of the dose. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">Etravirine</A>
          </B></TD><TD valign="top">Amprenavir AUC increased by 69%. </TD><TD valign="top">Manufacturer recommends avoiding co-administration, but clinical significance unclear. Consider FPV/r 700/100 mg twice-daily with standard dose <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">etravirine</A>. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">Maraviroc</A>
          </B></TD><TD valign="top">FPV/r may increase <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">maraviroc</A>'s serum concentrations. </TD><TD valign="top">No data. Consider FPV/r 700/100 mg twice-daily + <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">maraviroc</A> 150 mg twice-daily. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">Nevirapine</A>
          </B></TD><TD valign="top">APV serum concentration increased by 29% (compared to historical control). NVP increased 13%. . </TD><TD valign="top">FPV/r 700/100 mg twice-daily + <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg twice-daily</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">Indinavir</A>
          </B></TD><TD valign="top">APV AUC increased 33%. </TD><TD valign="top">Dose regimens not established. Avoid. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">Tipranavir</A>
          </B></TD><TD valign="top">APV AUC decreased 44% </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">Nelfinavir</A>
          </B></TD><TD valign="top">APV AUC increased 150%. </TD><TD valign="top">Inadequate data; avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">Delavirdine</A>
          </B></TD><TD valign="top">DLV AUC decreased 61%. APV AUC increased 130% </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">Atazanavir</A> (<A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>) </B></TD><TD valign="top"><A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> AUC decreased 22%. Fosamprenavir AUC increased 78%. </TD><TD valign="top">Clinical significance of a 22% decrease in <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> AUC unknown. Consider FPV/r 700/100 mg twice-daily + <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg once-daily. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir</A> (<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>) </B></TD><TD valign="top"><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> AUC decreased 14% (NS). </TD><TD valign="top">Limited data. Avoid or consider SQV/r 1000/100-200 mg twice-daily + FPV 700 mg twice-daily.</TD>
</TR>
<TR>
<TD valign="top"><B>Alfuzosin </B></TD><TD valign="top">May significantly increase alfuzosin serum concentrations. </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Alprazolam
          </B></TD><TD valign="top">May increase serum levels of alprazolam</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepine (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Amilodipine</B></TD><TD valign="top">May increase serum levels of amlodipine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Amiodarone</B></TD><TD valign="top">May significantly increase amiodarone serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case report of increased amiodarone levels with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> co-administration. The manufacturer of <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, APV, and <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> recommends against use of amiodarone, but all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the same potential of significantly increasing amiodarone serum levels. If co-administration can not be avoided, monitor for amiodarone ADRs (PFTs and TSH). Consider monitoring serum levels of amiodarone, but its long half-life may make titration difficult.</TD>
</TR>
<TR>
<TD valign="top"><B>Artemether (artemisinin)</B></TD><TD valign="top">May increase serum levels of artemether</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Close monitoring for artemether toxicity (bone marrow suppression, bradycardia, and seizure)</TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">May significantly increase astemizole serum levels</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Atorvastatin
          </B></TD><TD valign="top">Atorvastatin AUC increased by 130% (w/o <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>) and 150% (w/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>). No change in APV AUC.</TD><TD valign="top">Start with low doses (10-20 mg/d) and avoid doses &gt; 40 mg/d or consider alternative agents (pravastatin, fluvastatin, or possibly rosuvastatin).</TD>
</TR>
<TR>
<TD valign="top"><B>Azathioprine</B></TD><TD valign="top">Interaction unlikely</TD><TD valign="top">Applies to all PIs and NNRTI: Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Bepridil</B></TD><TD valign="top">May significantly increase bepridil serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. The manufacturer of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>, <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, and APV does not recommend bepridil co-administration, this contraindication should extend to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> since a significant increase in bepridil serum levels can result in pro-arrhythmic events such as VT, PVC, and VFib.</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">May decrease levels of PIs and NNRTI. PIs and NNRTI may increase or decrease carbamazepine levels.</TD><TD valign="top">Applies to all PIs and NNRTIs: Consider alternative anticonvulsants (valproic acid, lamotrigine, levetiracetam, or topiramate). Monitor carbamazepine levels and consider TDM of PIs and NNRTIs.</TD>
</TR>
<TR>
<TD valign="top"><B>Chlordiazepoxide</B></TD><TD valign="top">May increase serum levels of chlordiazepoxide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">May significantly increase cisapride serum levels.</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative: metoclopramide.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Clorazepate
          </B></TD><TD valign="top">May increase serum levels of clorazepate</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclophosphamide</B></TD><TD valign="top">May increase serum levels of cyclophosphamide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> resulting in a 50% increase in cyclophosphamide serum levels. Since all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of increasing cyclophosphamide levels, close monitoring of cyclophosphamide-induced toxicity is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">May significantly increase serum levels of cyclosporine</TD><TD valign="top">Applies to all PIs: Monitor serum levels of cyclosporine closely with co-administration. Cyclosporine dose may need to be decreased.</TD>
</TR>
<TR>
<TD valign="top"><B>Dexamethasone</B></TD><TD valign="top">May decrease APV serum levels</TD><TD valign="top">Use with caution. Consider boosting (FPV700mg+ <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100mg twice-daily).</TD>
</TR>
<TR>
<TD valign="top"><B>Digoxin </B></TD><TD valign="top">Digoxin serum concentration may be increased with FPV/r co-administration. </TD><TD valign="top">Monitor digoxin serum concentrations closely with co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Diltiazem</B></TD><TD valign="top">May increase serum levels of diltiazem</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with diltiazem co-administration. Diltiazem should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Disopyramide</B></TD><TD valign="top">May increase disopyramide serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Monitor disopyramide serum levels (target: 2-7.5 mcg/mL).</TD>
</TR>
<TR>
<TD valign="top"><B>Docetaxel</B></TD><TD valign="top">May increase serum levels of docetaxel</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Dofetilide</B></TD><TD valign="top">May significantly increase serum levels of dofetilide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor QTc closely and adjust dofetilide dosing based on QTc prolongation and renal function. Consider an alternative class III antiarrhythmic such as bretylium or ibutilide.</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot Alkaloid</B></TD><TD valign="top">May significantly increase serum levels of ergotamine resulting in acute ergot toxicity</TD><TD valign="top">Contraindicated. Consider alternative agent for migraine such as sumatriptan (but not eletriptan since it is a CYP3A4 substrate and significant drug interaction occurred with CYP3A4 inhibitor).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Estazolam
          </B></TD><TD valign="top">May increase serum levels of estazolam</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinyl estradiol/norethindrone </B></TD><TD valign="top">May increase ethinyl estradiol serum concentrations. APV serum concentrations may decrease. </TD><TD valign="top">Avoid co-administration. Ethinyl estradiol Cmin increased 32%. Norethindrone AUC increased 18%, and Cmin increased 45%. Amprenavir AUC decreased 22%, and Cmin decreased 20% (studied using old formulation of amprenavir) </TD>
</TR>
<TR>
<TD valign="top"><B>Ethosuximide</B></TD><TD valign="top">May increase serum levels of ethosuximide</TD><TD valign="top">Applies to All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider switching to valproic acid for the treatment of absence seizure.</TD>
</TR>
<TR>
<TD valign="top"><B>Etoposide</B></TD><TD valign="top">May increase serum levels of etoposide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Felodipine</B></TD><TD valign="top">May increase serum levels of felodipine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Flecainide</B></TD><TD valign="top">May increase serum levels of flecainide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Avoid co-administration; if necessary, monitor flecainide trough levels with co-administration. Target: 200-1000ng/ml. Toxicity is frequent with trough serum levels above 1000 ng/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Flurazepam
          </B></TD><TD valign="top">May increase serum levels of flurazepam</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Fluticasone </B></TD><TD valign="top">Fluticasone AUC increased 350-fold (studied with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg q12h).</TD><TD valign="top">Avoid long-term co-administration. Consider beclomethasone. </TD>
</TR>
<TR>
<TD valign="top"><B>Garlic Supplement </B></TD><TD valign="top">49% and 51% reduction in <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> AUC and Cmin, respectively </TD><TD valign="top">Studies only done with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>, but garlic may affect the serum levels of other PIs and NNRTIs. Avoid co-administration of garlic with other PIs and NNRTIs. </TD>
</TR>
<TR>
<TD valign="top"><B>Granisetron</B></TD><TD valign="top">May increase serum levels of granisetron</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Due to the large therapeutic index of granisetron, potential interaction is unlikely to be clinically significant.</TD>
</TR>
<TR>
<TD valign="top"><B>Heroin (Diamorphine)</B></TD><TD valign="top">Drug interactions unlikely</TD><TD valign="top">Applies to PIs and NNRTIs: Interaction unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Ifosphamide</B></TD><TD valign="top">May increase serum levels of ifosphamide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Irinotecan</B></TD><TD valign="top">May increase irinotecan serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Co-administration of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> is contraindicated by manufacturer. All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> also have the potential for significant interaction with irinotecan, therefore co-administration should be done with extreme caution.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">May increase itraconazole serum concentrations </TD><TD valign="top">Monitor for itraconazole serum concentrations. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">May increase ketoconazole serum concentrations</TD><TD valign="top">Do not exceed ketoconazole 200 mg/day. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">May increase APV and ketoconazole serum concentrations. </TD><TD valign="top">With old APV formulation, APV AUC increased 32% and ketoconazole AUC increased 44%.Use standard dose of both drugs, but do not exceed ketoconazole 200 mg/d. </TD>
</TR>
<TR>
<TD valign="top"><B>Lidocaine</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution, monitor lidocaine serum levels (target:1.5-6 mcg/mL) with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Lovastatin
          </B></TD><TD valign="top">Serum levels of lovastatin may be significantly increased</TD><TD valign="top">Contraindicated. Recommended alternatives include pravastatin, rosuvastatin, or fluvastatin (and atorvastatin - start with 10mg/d). Monitor for ADRs due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Maalox </B></TD><TD valign="top">APV AUC decreased by 18%</TD><TD valign="top">No significant interaction.</TD>
</TR>
<TR>
<TD valign="top"><B>Mefloquine</B></TD><TD valign="top">May increase serum levels of mefloquine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Monitor mefloquine serum levels and mefloquine-induced toxicity (i.e dizziness, LFTs, and periodic ophthalmic examination).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">May decrease methadone-R AUC by 13% (studied with APV) </TD><TD valign="top">Monitor for withdrawal symptoms. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">S-methadone serum concentrations may be decreased. </TD><TD valign="top">Studied with APV. S-methadone (active) was decreased 13% and APV AUC was decreased 25%; no withdrawal symptom observed. Co-administer with close monitoring. </TD>
</TR>
<TR>
<TD valign="top"><B>Mexiletine</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor EKG and serum levels. Serum levels exceeding 1.5-2 mcg/mL have been associated with an increased risk of toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Midazolam
          </B></TD><TD valign="top">May significantly increase midazolam levels</TD><TD valign="top">Chronic use of midazolam should be avoided; single use IV midazolam may be used. Consider alternative benzodiazepines(temazepam, oxazepam, or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Milk thistle </B></TD><TD valign="top">Data limited to a drug interaction study with milk thistle and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC unchanged but Cmin decreased by 47%. </TD><TD valign="top">Clinical significance unknown. May affect the serum levels of other PIs and NNRTIs. </TD>
</TR>
<TR>
<TD valign="top"><B>Mirtazapine</B></TD><TD valign="top">May increase serum levels of mirtazapine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine.)</TD>
</TR>
<TR>
<TD valign="top"><B>Mycophenolate</B></TD><TD valign="top">Interaction unlikely. No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>.</TD><TD valign="top">Applies to all PIs and NNRTI: No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Nefazodone</B></TD><TD valign="top">May increase serum levels of nefazodone</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine.)</TD>
</TR>
<TR>
<TD valign="top"><B>Nifedipine</B></TD><TD valign="top">May increase serum levels of nifedipine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Nisoldipine</B></TD><TD valign="top">May increase serum levels of nisoldipine</TD><TD valign="top">Applies to All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Paclitaxel
          </B></TD><TD valign="top">May significantly increase serum levels of paclitaxel</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case reports of severe toxicity associated with <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> and <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> co-administration with paclitaxel. Since all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of significantly increasing paclitaxel serum levels, close monitoring of paclitaxel- induced toxicity is recommended. </TD>
</TR>
<TR>
<TD valign="top"><B>PCP</B></TD><TD valign="top">May significantly increase serum levels of PCP</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital</B></TD><TD valign="top">May decrease serum levels of PIs and NNRTIs. PIs and NNRTIs may increase or decrease phenobarbital serum levels</TD><TD valign="top">Applies to all PIs and NNRTI: Consider alternative anticonvulsants (valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants levels and consider TDM of PIs and NNRTIs.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">May decrease serum levels of PIs and NNRTIs. PIs and NNRTIs may increase or decrease phenytoin serum levels.</TD><TD valign="top">Applies to all PIs and NNRTIs: Consider alternative anticonvulsants (valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants levels and consider TDM of PIs and NNRTIs.</TD>
</TR>
<TR>
<TD valign="top"><B>Pimozide</B></TD><TD valign="top">May significantly increase pimozide serum levels resulting in QTc prolongation.</TD><TD valign="top">Contraindicated. Consider alternative: Olanzapine.</TD>
</TR>
<TR>
<TD valign="top"><B>PPI</B></TD><TD valign="top">No significant interaction </TD><TD valign="top">FPV may be co-administered with PPI.</TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone</B></TD><TD valign="top">May significantly increase serum levels of propafenone</TD><TD valign="top">Contraindicated.</TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone</B></TD><TD valign="top">May significantly increase serum levels of propafenone</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Co-administration should be avoided. Serum levels are not routinely recommended due to the poor correlation with efficacy and toxicity. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Quinidine
          </B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Contraindicated with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>. With all Ps and NNRTIs co-administration, monitor EKG (QTc) and serum levels: target: 2-5 mcg/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Raltegravir
          </B></TD><TD valign="top">Interaction unlikely </TD><TD valign="top">No data, but <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (100 mg twice-daily) did not affect raltegravir PK parameters. Consider standard dose with close monitoring. </TD>
</TR>
<TR>
<TD valign="top"><B>Ranitidine</B></TD><TD valign="top">APV AUC decreased by 30%</TD><TD valign="top">With boosted FPV (FPV700mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100mg twice-daily); interaction not significant.</TD>
</TR>
<TR>
<TD valign="top"><B>Ranolazine </B></TD><TD valign="top">May significantly increase ranolazine serum concentrations. </TD><TD valign="top">Contraindicated. May increase risk of QTc prolongation. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin
          </B></TD><TD valign="top">Based on APV data, an increase in rifabutin levels is expected.</TD><TD valign="top">CDC recommendation: FPV 1400mg twice-daily + rifabutin 150mg once-daily OR 300g 3x/wk OR FPV 700mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100mg twice-daily + 150mg every other day OR 150mg 3x/wk.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifapentine
          </B></TD><TD valign="top">FPV serum levels may be significantly decreased</TD><TD valign="top">Avoid co-administration. Consider using rifabutin.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rosuvastatin
          </B></TD><TD valign="top">Other CYP3A4 inhibitor (i.e <A class="headLines" target="_new" href="../antimicrobial_agents/erythromycin329b.html?contentInstanceId=434157">erythromycin</A>) did not affect rosuvastatin serum levels.</TD><TD valign="top">Applies to PIs and NNRTI: Interaction unlikely, but close monitoring recommended due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">May increase sildenafil serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: .Start with 25 mg, and avoid dosing on consecutive days.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Simvastatin
          </B></TD><TD valign="top">May significantly increase simvastatin levels</TD><TD valign="top">Contraindicated. Alternatives include atorvastatin (start with 10-20 mg/d), pravastatin, rosuvastatin, or fluvastatin. Monitor for adverse effect due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus</B></TD><TD valign="top">May significantly increase serum levels of sirolimus</TD><TD valign="top">Applies to all PIs: Dose sirolimus based on serum levels. A significantly reduction of sirolimus dose with all PIs co-administration is highly likely.</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's wort</B></TD><TD valign="top">May significantly decrease FPV levels</TD><TD valign="top">Contraindicated. Use an alternative (more effective) antidepressant.</TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus</B></TD><TD valign="top">May significantly increase serum level of tacrolimus</TD><TD valign="top">Applies to all PIs: Dose tacrolimus based on serum level. A significantly reduction of tacrolimus dose with all PIs co-administration is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Tadalafil</B></TD><TD valign="top">May increase serum level of tadalafil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Start with 5 mg. Do not exceed 10 mg in 72 hrs. Consider sildenafil due to more clinical data and shorter half-life allowing for easier titration.</TD>
</TR>
<TR>
<TD valign="top"><B>Tamoxifen</B></TD><TD valign="top">May increase serum level of tamoxifen</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of Tamoxifen-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Teniposide</B></TD><TD valign="top">May increase serum level of teniposide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of teniposide-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine</B></TD><TD valign="top">May significantly increase terfenadine serum level</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine(loratadine, fexofenadine, desloratidine, or cetirizine).</TD>
</TR>
<TR>
<TD valign="top"><B>THC</B></TD><TD valign="top">Based on data with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> interactions are unlikely</TD><TD valign="top">Applies to PIs and NNRTIs: Interactions are unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Trazadone
          </B></TD><TD valign="top">May increase serum level of trazadone</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI:escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Triazolam
          </B></TD><TD valign="top">May significantly increase triazolam serum level.</TD><TD valign="top">Contraindicated. Consider alternative benzodiazepines (temazepam, oxazepam, and lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Vardenafil</B></TD><TD valign="top">May significantly increase serum level of vardenafil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Do not exceed vardenafil 2.5 mg in 72hrs (with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>) OR 2.5mg in 24 hrs (with other PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>). Consider sildenafil due to more clinical data and less pronounced interaction. Avoid co-administration with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>.</TD>
</TR>
<TR>
<TD valign="top"><B>Verapamil</B></TD><TD valign="top">May increase serum level of verapamil</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum level (this led PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging PR interval with Ca channel blocker coadministration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Vinblastine</B></TD><TD valign="top">May increase serum level of vinblastine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vinblastine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May increase serum level of vincristine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vincristine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Voriconazole
          </B></TD><TD valign="top">May decrease voriconazole AUC with FPV/r. Voriconazole may increase co-administered ART.</TD><TD valign="top">Significant interaction with &nbsp;<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (400mg twice-daily); contraindicated. Voriconazole AUC decreased 39% with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg/d co-administration; avoid co-administration with boosted PI. Consider another antifungal for aspergillosis (i.e ambisome or caspofungin) or use with TDM.</TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin </B></TD><TD valign="top">Case report of increased warfarin requirements after <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> initiation </TD><TD valign="top">Other PIs and NNRTIs may also affect warfarin requirements. Monitor INR closely with co-administration. </TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>As with other boosted PIs, PI mutations uncommon with failure of FPV/r in previously PI-naive pts </li>
<li>I50V: primary mutation selected by APV and FPV that confers intermediate resistance to APV and low-level resistance to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A>.</li>
<li>I54M/L: selected by APV and FPV, causes low-to-intermediate level APV resistance. </li>
<li>I84V: primary PI mutations that causes intermediate APV resistance.</li>
<li>Other PI mutations (10F/I/R/V, 32I, 46I/L, 47V, 54V, 73S, 76V, , 82A/F/S/T , 90M): increasing APV resistance with multiple mutations.</li>
<li>Predominant mutation observed in clinical trials: 32I, 33F, 46I, 47V, and 54L/V/M.</li>
<li>Use of FPV (without RTV) may lead to cross-resistance with <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">DRV</A> due to selection of <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">DRV</A> mutations (I50V, I54M/L, I84V, 32I, 33F, 47V). </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10FF1"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Rapidly hydrolyzed by cellular phosphatases to APV in the gut epithelium as it is absorbed. APV inhibits HIV protease, which results in nonfunctional, immature and non-infectious virions.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Independent of food.</li>
<li>Metabolism and Excretion: 
                Metabolized by CYP3A4. The metabolite is excreted primarily in feces (75%) with 14% excreted in urine</li>
<li>Protein Binding: 
                90%</li>
<li>Cmax, Cmin, and AUC: 
                Cmax= 4.85 mcg/ml, Cmin= 0.35mcg/ml after 1400mg dose.</li>
<li>T1/2: 
                7.7 hrs</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>No clinical data. Consider dose adjustment based on PK data: adjustment to 700 mg twice-daily with Child Pugh score 5-9 (in PI-naive pts); FPV/r 700/100 mg twice-daily; Child Pugh score 5-6 (in PI-naive or experienced); FPV/r 450/100 mg twice-daily with Child Pugh score 7-9 (PI-naive or experienced); FPV 350 mg twice-daily with Child Pugh 10-12 (PI-naive). No data with RTV boosting in severe hepatic impairment. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>No human data. Category C: Animal studies FPV showed no embryo-fetal development abnormalities, however rate of abortion was increased.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No data: not recommended in the U.S.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Equivalent to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> in treatment-naive pts; option for once-daily administration (with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> in PI-naive pts); can be taken with or without food; no significant PPI or H2 blocker drug-interactions; no PI resistance and reduced NRTI resistance with failure of FPV/r compared to FPV; FPV/r with lower dose RTV (1400/100 mg once-daily) effective in treatment naive pts with similar tolerability and lipid effects as ATV/r. </li>
<li>Cons: Higher pill burden than <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> or <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>/r; FPV/r has comparable ADRs to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> when used with 200 mg/d of RTV; may not be as effective as <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> in PI experienced pts. </li>
</ul>
<a name="N1104A"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Smith K., Weinberg W., DeJesus E. et al. ;
		Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.&nbsp;;        
		AIDS Res Ther. ;
		2008 ; Vol. 
		28 ; pp. 
		5 ;
		<br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=18373851&amp;dopt=abstract" target="_new">18373851 </a>
<br>
<b>Comments:</b>Randomized clinical trial involving 106 antiretroviral-naive, HIV-1-infected patients. Pts received either FPV/r 1400 mg/100 mg daily or ATV/r 300/100 mg daily, each with the co-formulation of TDF/FTC 300 mg/200 mg once-daily. At week 48, virologic suppression of daily FPV/r was comparable to ATV/r treated group, with 83% of patients in the ATV/r group and 75% in the FPV/r group achieving HIV-1 RNA VL &lt;less than 50 copies per mL (p=0.338) Note: this study was underpowered. No significant LDL elevation was observed between the two groups; however, triglyceride elevation was slightly higher in the FPV/r treated group (34 vs 7 g/dL increase from baseline). Diarrhea was reported in 53% and 25% of FPV/r and ATV/r-treated pts, respectively. <br>
<br>
</li>
<li>Eron J, Yeni P, Gathe J, et al.;
		The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.;        
		Lancet;
		2006; Vol. 
		368; pp. 
		476-82;
		<br>ISSN:
	        	1474-547X;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16890834&amp;dopt=abstract" target="_new">16890834 </a>
<br>
<b>Comments:</b>Open-label, randomized study involving 878 naive pts with med. Pts were randomized to received each FPV/r 700/100 mg twice-daily or <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 400/100 mg twice-daily, each with the co-formulation of <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">abacavir</A>-<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">lamivudine</A> 600 mg/300 mg once daily. At week 48, non-inferiority of fosamprenavir-<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> to lopinavir-<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> (95% CI around the treatment difference -4.84 to 7.05) was shown, with 73% patients in the FPV/r group and 71% in the <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> group achieving HIV-1 RNA less than 400 copies per mL. ADRs were also comparable between the two groups. <br>
<br>
</li>
<li>Gathe JC, Ive P, Wood R, et al. ;
		SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.;        
		AIDS. ;
		2004 ; Vol. 
		18 ; pp. 
		1529-37 ;
		<br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15238771&amp;dopt=abstract" target="_new">15238771 </a>
<br>
<b>Comments:</b>Open-label, randomized study involving 649 naive pts with med. CD4 of 170 and VL of 4.81 log. Pts received FPV 1400 mg once-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg once-daily + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> twice-daily or <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 mg twice-daily + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> twice-daily. ITT analysis: VL &lt;400 through wk 48 in 69% of FPV-treated pts and 68% of <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>-treated pts, difference of 1% (95% CI, -6%, 8%). VL &lt;50 through wk 48 in 55% of FPV-treated pts vs. 53% of <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>-treated pts. In a sub-analysis pts with VL &gt;100,000, both FPV and <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> (66% vs. 64%, respectively) achieved VL &lt;400. Daily FPV/r equivalent to <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> in PI-naive pts. Unfortunately, this study compared FPV with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> , a PI known to have inferior efficacy and PK profile compared to other agents in its class. <br>
<br>
</li>
<li>Rodriguez-French A, Boghossian J, Gray GE, et al.;
		The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.;        
		J Acquir Immune Defic Syndr;
		2004; Vol. 
		35; pp. 
		22-32;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=14707788&amp;dopt=abstract" target="_new">14707788</a>
<br>
<b>Comments:</b>Open-label, randomized study involving 249 naive pts with med CD4 212 and VL 4.83 log. Pts received FPV 1400 mg twice-daily + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> 150 twice-daily OR <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 mg twice-daily + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> twice-daily. ITT analysis: VL &lt;400 through wk 48 in 66% of FPV-treated pts vs 51% of <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>-treated pts, difference of 15% (95% CI, 2%, 28%). VL &lt;50 through wk 48 in 55% of FPV-treated pts vs. 41% of <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> -treated pts, difference of 14% (95% CI 2%, 27%). FPV more effective in pts with VL&gt;100,000 vs. <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> (55% vs. 24% VL &lt;50 , respectively). Mean VL comparable between groups at wk 48: -2.41 log for the FPV group and -2.32 log1 for the <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> group. Mean treatment difference in "average change in viral load" or average AUC minus baseline (AAUCMB) was -0.08 (95% CI: -0.333 to 0.169). Study showed that FPV (unboosted) is non-inferior to <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>. <br>
<br>
</li>
<li>DeJesus E, LaMarca A, Sension M, et al. ;
		The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced Subjects with Virological Failure (24 Week Results). ;        
		Abstract 178 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003. Boston, MA, USA. ;
		<br>
<b>Comments:</b>Open label, randomized study involving 315 pts with virologic failure on 1 or 2 prior PI-containing regimens. Med. CD4 263 and VL 4.14 log. Time-average change in VL from baseline at 48 wks were -1.53 log for twice-daily FPV and -1.76 log for <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>, difference of 0.244 (97.5% CI -0.017, 0.561). VL &lt;50 through wk 48 observed in 37%, 46%, and 50% receiving once-daily FPV, twice-daily FPV, and <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>, respectively. Once-daily FPV performed poorly and should not be used in PI-experienced pts. Trend favoring <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> ,although time-average change in VL from baseline not statistically different vs twice-daily FPV/r. In PI-experienced pts, FPV 700 mg twice-daily + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg twice-daily is not "non-inferior" to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> as defined by the time-average decline in VL from baseline. It should be noted that secondary endpoint of VL &lt; 50 at 48 wks was under powered to detect difference between treatment groups.<br>
<br>
</li>
</ol>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_fosamprenavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:51 GMT -->
</html>
